Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis
Open Access
- 29 September 2020
- journal article
- review article
- Published by MDPI AG in Nanomaterials
- Vol. 10 (10), 1945
- https://doi.org/10.3390/nano10101945
Abstract
Liver fibrosis, a reversible pathological process of inflammation and fiber deposition caused by chronic liver injury and can cause severe health complications, including liver failure, liver cirrhosis, and liver cancer. Traditional diagnostic methods and drug-based therapy have several limitations, such as lack of precision and inadequate therapeutic efficiency. As a medical application of nanotechnology, nanomedicine exhibits great potential for liver fibrosis diagnosis and therapy. Nanomedicine enhances imaging contrast and improves tissue penetration and cellular internalization; it simultaneously achieves targeted drug delivery, combined therapy, as well as diagnosis and therapy (i.e., theranostics). In this review, recent designs and development efforts of nanomedicine systems for the diagnosis, therapy, and theranostics of liver fibrosis are introduced. Relative to traditional methods, these nanomedicine systems generally demonstrate significant improvement in liver fibrosis treatment. Perspectives and challenges related to these nanomedicine systems translated from laboratory to clinical use are also discussed.Keywords
This publication has 121 references indexed in Scilit:
- The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapyChemical Society Reviews, 2012
- Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxideNanotechnology, 2010
- Reduced liver fibrosis in hypoxia-inducible factor-1α-deficient miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Magnetic nanoparticles in MR imaging and drug deliveryAdvanced Drug Delivery Reviews, 2008
- Diagnosis and Quantitation of FibrosisGastroenterology, 2008
- Combination of N‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitisHepatology Research, 2007
- Is vitamin E beneficial in chronic liver disease?Hepatology, 2007
- Inhibition of Hepatic Stellate Cell Proliferation and Activation by the Semisynthetic Analogue of Fumagillin TNP-470 in RatsHepatology, 2000
- Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cellsHepatology, 2000
- Protease inhibitors suppress TGF-β generation by hepatic stellate cellsJournal of Hepatology, 1998